文献速递关节外科

氨甲环酸联合可吸收止血剂减少全膝关节置换术围手术期失血的疗效与安全性:一项前瞻性盲法随机对照试验

Efficacy and Safety of Tranexamic Acid Combined with Absorbable Hemostat in Reducing Perioperative Blood Loss in Total Knee Arthroplasty: A Prospective, Blinded, Randomized Controlled Trial.
PubMed 文献 · J Bone Joint Surg Am · 2025-08-22

该研究先通过体外凝血试验、乳酸脱氢酶活性测定、扫描电镜及兔肝出血模型初步评估氨甲环酸(TXA)联合可吸收止血剂(AH)的止血效果与生物相容性,随后在前瞻性盲法随机对照试验中纳入149例个体随机接受TXA、AH或TXA+AH,其中114例汉族(东亚)患者的临床结果显示联合组围手术期失血量显著低于单用组,且未增加血栓栓塞事件或伤口相关并发症,并加速早期膝关节功能恢复。

要点

  • TXA+AH组围手术期失血量为564.51±136.26 mL,显著低于TXA组的879.35±85.62 mL和AH组的692.70±96.06 mL(p < 0.001)。
  • 联合组未增加血栓栓塞事件或伤口相关并发症。
  • 联合组加速术后早期膝关节功能恢复,对疼痛评分或炎症标志物无显著影响。

核心结论

  • TXA联合AH有效减少全膝关节置换术围手术期失血量,加速患者早期康复,且不增加并发症发生率。

研究设计与样本

  • 前瞻性、盲法、随机对照试验,纳入149例个体随机接受TXA、AH或TXA+AH,其中114例汉族(东亚)患者临床结果报告。
  • 体外动态凝血试验、乳酸脱氢酶活性测定、扫描电镜及兔肝出血模型初步评估止血效果与生物相容性。

主要发现

  • 体外凝血试验和兔肝止血模型显示TXA联合AH有效促进凝血,生物相容性满意。
  • TXA+AH组围手术期失血量为564.51±136.26 mL,TXA组为879.35±85.62 mL,AH组为692.70±96.06 mL,p < 0.001。
  • 联合组未增加血栓栓塞事件或伤口相关并发症。
  • 联合组加速术后早期膝关节功能恢复,对疼痛评分或炎症标志物无显著影响。

临床怎么用

  • 作者结论认为TXA联合AH可有效减少全膝关节置换术围手术期失血量、加速早期康复且不增加并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid (TXA) and absorbable hemostat (AH) are widely used to reduce perioperative blood loss in total knee arthroplasty (TKA). However, the efficacy of single-method hemostatic strategies is increasingly insufficient for meeting clinical demands. This study tested the efficacy and safety of TXA combined with AH for perioperative blood management in TKA. METHODS: Hemostatic efficacy was preliminarily evaluated through in vitro dynamic coagulation assays, lactate dehydrogenase activity measurements, and scanning electron microscopy, as well as in vivo using a rabbit liver bleeding model. The in vivo biocompatibility was also measured. Subsequently, the efficacy and safety of TXA combined with AH were further evaluated in a prospective, blinded study involving 149 individuals who were randomized to receive TXA, AH, or TXA+AH during TKA. The primary outcomes were perioperative blood loss, blood transfusion, hemoglobin and hematocrit levels, maximum hemoglobin change, anemia, and postoperative complications. Secondary outcomes included perioperative inflammation, coagulation function, and knee joint function. RESULTS: Coagulation assays and the liver hemostasis model demonstrated that TXA combined with AH effectively promoted coagulation, with satisfactory biocompatibility. The clinical results of 114 Han Chinese (East Asian) patients indicated that the combination significantly reduced perioperative blood loss in TKA (564.51 ± 136.26 mL in the TXA+AH group, 879.35 ± 85.62 mL in the TXA group, and 692.70 ± 96.06 mL in the AH group; p < 0.001) without an increase in thromboembolic events or wound-related complications. Additionally, the combination accelerated early postoperative knee function recovery without significantly affecting pain scores or inflammatory markers. CONCLUSIONS: The combination of TXA and AH effectively reduced perioperative blood loss in TKA, accelerated early patient recovery, and did not increase the rate of complications. LEVEL OF EVIDENCE: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Zhang QY, Wang G, Qu JH, et al. Efficacy and Safety of Tranexamic Acid Combined with Absorbable Hemostat in Reducing Perioperative Blood Loss in Total Knee Arthroplasty: A Prospective, Blinded, Randomized Controlled Trial. J Bone Joint Surg Am. 2025. PMID: 40845176. doi:10.2106/JBJS.24.01236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。